Thrombin Receptor Involvement in Diabetic Cardiomyopathy

Identifying new targets for the treatment of heart failure in patients with diabetic cardiomyopathy

Full Project Name:Thrombin Receptor Involvement in Diabetic CardiomyopathyPrincipal Investigator:Jennifer Strande, MD, PhD, MedicineAward Amount:500,000
Award Date
March2011
Project Duration:42 months

Project Description Narrative:


Cardiovascular disease is the No. 1 cause of death in the United States. As of 2006, more than 81 million Americans suffer from some form of cardiovascular disease with 8.5 million people experiencing a heart attack and 5.8 million suffering from heart failure. Nearly 2,300 Americans die of cardiovascular disease each day, claiming more lives each year than cancer, chronic lower respiratory diseases and accidents combined. In addition, heart disease contributes to an increase of poor health and poor quality of life. The costs associated with cardiovascular disease are estimated to be over $503 billion as of 2010. Despite advancements in medical therapy, cardiovascular disease remains a chronic and progressive process, underscoring the need for new medications to prevent heart attacks and heart failure.

Alongside cardiovasular disease, diabetes is a an increasingly prevalent condition, affecting nearly 420,000 adults and 6,000 children and adolescents in Wisconsin with an estimated direct and indirect cost totaling $5.26 billion. People with diabetes are at an increased risk of diabetes-related complications including cardiovascular disease.

Through this award, investigators aim to identify potential new targets for the treatment of heart failure in patients and the basis for future clinical treatments by identifying thrombin receptors contributing to cardiomyopathy.

Outcomes & Lessons Learned:


• Initiated study of how the thrombin receptor contributes to cardiomyopathy by increasing cardiac fibrosis, especially in the setting of diabetes

• Identified that inhibiting the thrombin receptor protects the heart against injury and subsequent development of cardiac fibrosis

• Documented no increased activity of the thrombin receptor in the heart within the setting of experimental diabetes or high glucose conditions. Results do not suggest that diabetes worsens cardiac injury

• Disseminated findings through various publications, presentations, and poster sessions

AHW Logo

8701 W Watertown Plank Road,
Milwaukee, WI 53226-0509
(414) 955-4350

©2021 MEDICAL COLLEGE OF WISCONSIN. ALL RIGHTS RESERVED | MCW.EDU | TERMS & PRIVACY | NON-DISCRIMINATION NOTICE

top